Mesothelioma: A Killer Lurks in the Lungs

Mesothelioma & Asbestos News Page

Home Page

St. Paul Asbestos Settlement Approved

The settlement ../includes $445 million for claimants and $57.5 million in fees.

According to Reuters:

Insurer St. Paul Travelers Companies on Wednesday said a bankruptcy court approved a $502.5 million asbestos settlement for all pending asbestos court actions against its Travelers Property Casualty unit.

Back to Original Article on Mesothelioma

Back to News Page

Continue with:

Asbestos Patients Analyzed by B-Certified Radiologists The extent to which asbestos has damaged a set of lungs or even caused a case of mesothelioma in certain patients is analyzed by expert radiologists.

Studies Find No Evidence That SV40 is Related to Human Cancer Two upcoming studies by scientists at the National Cancer Institute (NCI), one of the National Institutes of Health, provide further evidence that exposure to simian virus 40 (SV40) is not associated with cancer in humans.

Celebrex Hits Mesothelioma, in Lab Studies May 6, 2004 The COX-2 inhibitor Celebrex, usually prescribed for arthritis, has a marked effect on the asbestos-related cancer malignant mesothelioma in lab and animal experiments, according to a report from Italy

FDA Approves Alimta-Cisplatin Combination for Treatment of Asbestos-Related Cancer Mesothelioma The first and only drug regimen proven to help patients with an asbestos-related cancer live longer was approved today by the U.S. Food and Drug Administration (FDA).

Group Launches Asbestos-Cancer Study April 5, 2004 DETROIT - Karmanos Cancer Center is launching a comprehensive medical program to study the effects of asbestos-related cancers linked with contaminated vermiculite, a mineral used in insulation.

Study Supports Development Potential in Several Therapeutic Areas New Study Reviews Novel Approach to Control Inflammation Using Melanocortin Receptors WOODLAND HILLS, Calif., March 3 /PRNewswire/ -- Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be a novel strategy to control inflammatory disorders.

FDA Approves First Drug for Rare Type of Cancer The Food and Drug Administration (FDA) today approved Alimta (pemetrexed disodium) for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma - a rare type of cancer. Alimta received a priority review and is designated as an orphan drug. It is the first drug approved for this condition.